Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 4/20 | 0.61 |
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26619406 | 0.89 | OPRD1 (0.59) | OPRD1LTA4HKDM4EALDH1A1SIGMAR1 | |
| SCHEMBL26619452 | 0.89 | OPRD1 (0.58) | OPRD1LTA4HKDM4EALDH1A1 | |
| SCHEMBL1189890 | 0.87 | OPRD1 (0.62) | OPRD1KDM4EALDH1A1 | |
| SCHEMBL26619347 | 0.87 | OPRD1 (0.62) | OPRD1KDM4EALDH1A1 | |
| SCHEMBL27010107 | 0.83 | OPRD1 (0.58) | OPRD1 | |
| SCHEMBL1189408 | 0.82 | OPRD1 (0.56) | OPRD1LTA4H | |
| SCHEMBL26619426 | 0.82 | OPRD1 (0.57) | OPRD1KDM4EALDH1A1 | |
| SCHEMBL24447814 | 0.82 | MAPK1 (0.59) | OPRD1ALDH1A1 | |
| SCHEMBL11990423 | 0.82 | MAPK1 (0.59) | OPRD1ALDH1A1 | |
| SCHEMBL26619435 | 0.81 | SIGMAR1 (0.50) | OPRD1LTA4HKDM4ESIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2022081927-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | OPRD1 3365/4885LTA4H 3441/4885KDM4E 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.